US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ARS PHARMACEUTICALS INC

14.42

+0.04000.28%

Volume:160.05K

Turnover:2.32M

Market Cap:1.41B

PE:180.25

High:14.73

Open:14.46

Low:14.29

Close:14.38

Loading ...

Overview Company News Filings

ARS Pharmaceuticals on Track for Record Winning Streak -- Data Talk

ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools

U.S. Weekly Review: Stock Market Rises On Tame Inflation, Bank Earnings

Investor’s Business Daily

Stock Track | ARS Pharmaceuticals Inc (SPRY) Soars 5.55% on Analyst Optimism

Analysts Are Bullish on These Healthcare Stocks: Kura Oncology (KURA), ARS Pharmaceuticals (SPRY)

ARS Pharmaceuticals Is Maintained at Strong Buy by Raymond James

Raymond James Sticks to Its Buy Rating for ARS Pharmaceuticals (SPRY)

ARS Pharmaceuticals Inc : Raymond James Raises Target Price to $28 From $26

THOMSON REUTERS

ARS Pharmaceuticals Inc : Leerink Partners Raises Target Price to $27 From $26

THOMSON REUTERS

Corrected-ARS Pharmaceuticals Q4 Neffy Product Revenue of USD 6.5 Million (Corrects to Clarify Amount Is Not for Co's 'Revenue', and Removes Reference to Estimate)

THOMSON REUTERS

ARS Pharmaceuticals Q4 Revenue USD 6.5 Million VS. Ibes Estimate USD 17 Million

THOMSON REUTERS

Press Release: ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy(R) (epinephrine nasal spray)

ARS Pharmaceuticals files for approval of neffy in Canada, U.K.

ARS Pharmaceuticals Files for Approval of Experimental Allergic Reaction Treatment in Canada, UK

MT Newswires Live

ARS Pharmaceuticals Files for Approval of Neffy® in Canada and the United Kingdom on Behalf of Licensing Partner Alk-AbellÓ a/S

THOMSON REUTERS

Institutional owners may ignore ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) recent US$67m market cap decline as longer-term profits stay in the green

Simply Wall St.

ARS Pharmaceuticals adds neffy to Commercial national formularies

ARS Pharmaceuticals' Licensing Partners in China, Japan, Australia Seek Approval on Neffy Nasal Spray

MT Newswires Live

BRIEF-ARS Pharmaceuticals Announces Filings For Approval Of Neffy In China, Japan And Australia

ARS Pharmaceuticals notes filings for neffy approval in China, Japan, Australia

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SPRY/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SPRY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRY\",,,,,undefined,":{"symbol":"SPRY","market":"US","secType":"STK","nameCN":"ARS PHARMACEUTICALS INC","latestPrice":14.42,"timestamp":1745509450757,"preClose":14.38,"halted":0,"volume":160051,"delay":0,"floatShares":47453121,"shares":98119804,"eps":0.079999,"marketStatus":"Trading","change":0.04,"latestTime":"04-24 11:44:17 EDT","open":14.46,"high":14.73,"low":14.2925,"amount":2323868.016897,"amplitude":0.030424,"askPrice":14.44,"askSize":206,"bidPrice":14.39,"bidSize":377,"shortable":3,"etf":0,"ttmEps":0.079999,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745524800000},"marketStatusCode":2,"adr":0,"listingDate":1607058000000,"exchange":"NASDAQ","adjPreClose":14.38,"preHourTrading":{"tag":"盘前","latestPrice":14.38,"preClose":14.38,"latestTime":"08:16 EDT","volume":605,"amount":9218.68024,"timestamp":1745496969560},"postHourTrading":{"tag":"盘后","latestPrice":14.53,"preClose":14.38,"latestTime":"19:48 EDT","volume":12179,"amount":175271.83,"timestamp":1745452088274},"volumeRatio":0.282603,"impliedVol":0.7774,"impliedVolPercentile":0.536},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRY\",,,,,undefined,":{"symbol":"SPRY","floatShares":47453121,"roa":"-0.66%","roe":"3.28%","lyrEps":0.082507,"volumeRatio":0.282603,"shares":98119804,"dividePrice":0,"high":14.73,"amplitude":0.030424,"preClose":14.38,"low":14.2925,"week52Low":7.55,"pbRate":"5.51","psRate":"15.87","week52High":18.51,"institutionHeld":0,"latestPrice":14.42,"committee":0.29331,"eps":0.079999,"divideRate":0,"volume":160051,"delay":0,"ttmEps":0.079999,"open":14.46,"prevYearClose":10.55,"prevWeekClose":14.88,"prevMonthClose":12.58,"prevQuarterClose":12.58,"fiveDayClose":14.88,"twentyDayClose":12.6,"sixtyDayClose":14.88},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SPRY\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2506581500","title":"ARS Pharmaceuticals on Track for Record Winning Streak -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2506581500","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506581500?lang=en_us&edition=fundamental","pubTime":"2025-01-28 03:55","pubTimestamp":1738007700,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals, Inc.  is currently at $14.16, up $0.08 or 0.6%. --Would be highest close since Dec. 4, 2024, when it closed at $14.42. --Currently up 10 consecutive days; up 26.02% over this period. --Down 76.55% from its all-time closing high of $60.41 on March 17, 2021. --Up 118.6% from 52 weeks ago , when it closed at $6.48. --Down 19.01% from its 52-week closing high of $17.49 on Nov. 11, 2024. --Traded as high as $15.19; highest intraday level since Nov. 14, 2024, when it hit $15.25. --Up 7.88% at today's intraday high; largest intraday percent increase since Jan. 13, 2025, when it rose as much as 11.03%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2505122714","title":"ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools","url":"https://stock-news.laohu8.com/highlight/detail?id=2505122714","media":"GlobeNewswire","labels":["productRelease","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505122714?lang=en_us&edition=fundamental","pubTime":"2025-01-21 21:00","pubTimestamp":1737464400,"startTime":"0","endTime":"0","summary":"School administrators and nurses are encouraged to review applicable state laws and regulations to ensure neffy  2 mg for undesignated use meets applicable state law requirements. SAN DIEGO, Jan. 21, 2025  -- ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today the launch of the neffyinSchools program. neffyinSchools provides eligible public and private K-12 schools in the U.S. with the opportunity to receive two cartons  of neffy  2 mg for use in emergency situations at no cost to the school via the School Health Corp. SHConnect platform. neffy 2 mg is approved for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh ≥30 kg . Participating schools will be eligible to receive replacement doses when the product is used or expires.ARS Pharma will host a webinar for school nurses and a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-launches-neffyinschools-program-130000908.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools","news_tag":"productRelease,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2504419355","title":"U.S. Weekly Review: Stock Market Rises On Tame Inflation, Bank Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2504419355","media":"Investor’s Business Daily","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504419355?lang=en_us&edition=fundamental","pubTime":"2025-01-18 10:06","pubTimestamp":1737165989,"startTime":"0","endTime":"0","summary":"The stock market rebounded to or above key levels on tame inflation data and strong bank earnings. Many stocks flashed buy signals.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/stock-market-rises-tame-inflation-bank-earnings/","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["NEO","AEO","HRMY","HEES","ANF","NVDX","AXSM","PLNT","NVDD","URI","NVDS","BLK","TSM","ELV","BBIO","CI","JNJ","NVDU","REGN","TGT","URBN","BAC","UNH","LULU","SPRY","CNC","LTH","NVD","ITCI"],"gpt_icon":1},{"id":"1168940774","title":"Stock Track | ARS Pharmaceuticals Inc (SPRY) Soars 5.55% on Analyst Optimism","url":"https://stock-news.laohu8.com/highlight/detail?id=1168940774","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168940774?lang=en_us&edition=fundamental","pubTime":"2025-01-15 22:32","pubTimestamp":1736951541,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc  stock soared 5.55% in Wednesday's intraday trading, following bullish analyst sentiment on the healthcare company.According to analyst reports, there is growing optimism surrounding ARS Pharmaceuticals and its peers in the healthcare sector. Analysts have issued favorable recommendations on SPRY, citing the company's strong prospects and growth potential.The positive analyst coverage has fueled investor confidence in ARS Pharmaceuticals, driving the stock's significant i","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | ARS Pharmaceuticals Inc (SPRY) Soars 5.55% on Analyst Optimism","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"2503615351","title":"Analysts Are Bullish on These Healthcare Stocks: Kura Oncology (KURA), ARS Pharmaceuticals (SPRY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503615351","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503615351?lang=en_us&edition=fundamental","pubTime":"2025-01-15 18:30","pubTimestamp":1736937019,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kura Oncology (KURA – Research Report) and ARS Pharm...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-kura-oncology-kura-ars-pharmaceuticals-spry?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-kura-oncology-kura-ars-pharmaceuticals-spry?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","SPRY","KURA","BK4139","BK4137","BK4505"],"gpt_icon":0},{"id":"2503504661","title":"ARS Pharmaceuticals Is Maintained at Strong Buy by Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2503504661","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503504661?lang=en_us&edition=fundamental","pubTime":"2025-01-15 01:45","pubTimestamp":1736876700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPRY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 14, 2025 12:45 ET (17:45 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RJF","SPRY"],"gpt_icon":0},{"id":"2503257695","title":"Raymond James Sticks to Its Buy Rating for ARS Pharmaceuticals (SPRY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503257695","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503257695?lang=en_us&edition=fundamental","pubTime":"2025-01-14 22:16","pubTimestamp":1736864164,"startTime":"0","endTime":"0","summary":"In a report released today, Ryan Deschner from Raymond James maintained a Buy rating on ARS Pharmaceuticals (SPRY – Research Report), with a price ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/raymond-james-sticks-to-its-buy-rating-for-ars-pharmaceuticals-spry?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/raymond-james-sticks-to-its-buy-rating-for-ars-pharmaceuticals-spry?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRY","RJF"],"gpt_icon":0},{"id":"2503221745","title":"ARS Pharmaceuticals Inc : Raymond James Raises Target Price to $28 From $26","url":"https://stock-news.laohu8.com/highlight/detail?id=2503221745","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503221745?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:47","pubTimestamp":1736858843,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nFWN3OA162:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2503309634","title":"ARS Pharmaceuticals Inc : Leerink Partners Raises Target Price to $27 From $26","url":"https://stock-news.laohu8.com/highlight/detail?id=2503309634","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503309634?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:01","pubTimestamp":1736773295,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nFWN3O916Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2503589270","title":"Corrected-ARS Pharmaceuticals Q4 Neffy Product Revenue of USD 6.5 Million (Corrects to Clarify Amount Is Not for Co's 'Revenue', and Removes Reference to Estimate)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503589270","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503589270?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:00","pubTimestamp":1736773201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nPLX0C6208:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2503098253","title":"ARS Pharmaceuticals Q4 Revenue USD 6.5 Million VS. Ibes Estimate USD 17 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2503098253","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503098253?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:00","pubTimestamp":1736773201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nPLX0C6208:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2503309516","title":"Press Release: ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy(R) (epinephrine nasal spray)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503309516","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503309516?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:00","pubTimestamp":1736773200,"startTime":"0","endTime":"0","summary":"Preliminary fourth quarter neffy net product revenue of approximately $6.5 million. Preliminary cash, cash equivalents and short-term investments of $314.0 million at year-end 2024 to support an operating runway of at least three years. Company to present at 43 Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 7:30am PT. SAN DIEGO, Jan. 13, 2025  -- ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced preliminary, unaudited neffy  net product revenue for the fourth quarter and full year 2024 and outlined its 2025 commercial and clinical objectives.-- Product revenue: Preliminary neffy net product revenue for the fourth. quarter of 2024 was approximately $6.5 million, with total net product. sales for 2024 of approximately $7.1 million since neffy became available. to wholesalers and pharmacies on Septemb","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4561","CME","BK4232","BK4139","LU2089284900.SGD","LU2133065610.SGD","LU2089283258.USD","LU0912757837.SGD","LU0950375773.USD","LU0823417653.USD","LU1732800096.USD","LU1599440770.SGD","LU0731783394.SGD","LU1718418525.SGD","IE00B3PB1722.GBP","IE00BVYPNV92.GBP","LU1732799900.SGD","IE00B42XCP33.USD","R","BK4112","LU2506951958.HKD","LU2023251221.USD","LU0823417737.USD","BK4022","LU2506952097.USD","LU2347655156.SGD","LU2237438978.USD","LU2506951875.HKD","IE00BGHQF631.EUR","SPRY","BK4566","IE00B3T34201.USD","LU0158827948.USD","LU0795875169.SGD","LU2506952170.USD","BK4585","IE00BDGV0183.EUR","BK4588","LU0795875086.SGD","IE00BVYPNW00.USD"],"gpt_icon":0},{"id":"2501202154","title":"ARS Pharmaceuticals files for approval of neffy in Canada, U.K.","url":"https://stock-news.laohu8.com/highlight/detail?id=2501202154","media":"TipRanks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501202154?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:15","pubTimestamp":1736255711,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals  announced that ARS Pharma has filed for approval of neffy 2 mg in Canada and the United Kingdom, where it will be marketed as EURneffy, on behalf of its licensing partner, ALK- Abello A/S. neffy was recently approved in the U.S. for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh greater than or equal to30 kg. In November 2024, ARS Pharma announced a licensing agreement providing ALK with exclusive rights to commercialize neffy in Europe, Canada, United Kingdom and certain other geographies outside of the U.S.Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. ARS Pharmaceuticals adds neffy to Commercial national formularies. ARS Pharmaceuticals notes filings for neffy approval in China, Japan, Australia. ARS Pharmaceuticals files for approval of neffy in China, Japan and Australia","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/ars-pharmaceuticals-files-approval-neffy-131511272.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-files-approval-neffy-131511272.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2501519672","title":"ARS Pharmaceuticals Files for Approval of Experimental Allergic Reaction Treatment in Canada, UK","url":"https://stock-news.laohu8.com/highlight/detail?id=2501519672","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501519672?lang=en_us&edition=fundamental","pubTime":"2025-01-07 00:06","pubTimestamp":1736179562,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals  said Monday it has filed for approval of the neffy epinephrine nasal spray for the treatment of type I allergic reactions in Canada and the UK on behalf of its licensing partner, ALK-Abello.The company said it is assessing its intranasal epinephrine technology to treat acute flares in patients with chronic urticaria. It intends to initiate a phase 2b clinical trial early this year.ARS Pharmaceuticals also said its license deal with ALK will provide them exclusive rights for any new indication in the licensed territories under the agreement.Shares of the company declined more than 1% in recent trading activity.Price: 10.99, Change: -0.21, Percent Change: -1.83","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2501239028","title":"ARS Pharmaceuticals Files for Approval of Neffy® in Canada and the United Kingdom on Behalf of Licensing Partner Alk-AbellÓ a/S","url":"https://stock-news.laohu8.com/highlight/detail?id=2501239028","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501239028?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:14","pubTimestamp":1736169290,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nFWN3O1023:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2493033776","title":"Institutional owners may ignore ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) recent US$67m market cap decline as longer-term profits stay in the green","url":"https://stock-news.laohu8.com/highlight/detail?id=2493033776","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493033776?lang=en_us&edition=fundamental","pubTime":"2024-12-24 23:24","pubTimestamp":1735053852,"startTime":"0","endTime":"0","summary":"Given the large stake in the stock by institutions, ARS Pharmaceuticals' stock price might be vulnerable to their trading decisions. 54% of the business is held by the top 8 shareholders. To get a sense of who is truly in control of ARS Pharmaceuticals, Inc. , it is important to understand the ownership structure of the business. We can see that institutions own the lion's share in the company with 36% ownership. In other words, the group stands to gain the most  from their investment into the company.No shareholder likes losing money on their investments, especially institutional investors who saw their holdings drop 5.8% in value last week. However, the 117% one-year returns may have helped alleviate their overall losses. We would assume however, that they would be on the lookout for weakness in the future.Let's take a closer look to see what the different types of shareholders can tell us about ARS Pharmaceuticals.Check out our latest analysis for ARS Pharmaceuticals. What Does The ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/institutional-owners-may-ignore-ars-152412062.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRY","PSQ","TQQQ","BK4112","QID","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SQQQ","MNQmain","BK4588",".IXIC","LU2095319765.USD","BK4585","QLD","TSYW.SI","IE00BGHQF748.EUR","IE00B64PRP62.GBP","USJW.SI","BK4139","LU2210150020.SGD","LU2210149790.SGD","NDAQ","USAW.SI","NVIW.SI","NQmain"],"gpt_icon":1},{"id":"2492577438","title":"ARS Pharmaceuticals adds neffy to Commercial national formularies","url":"https://stock-news.laohu8.com/highlight/detail?id=2492577438","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492577438?lang=en_us&edition=fundamental","pubTime":"2024-12-20 06:30","pubTimestamp":1734647418,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals (SPRY) “announced that Express Scripts, the pharmacy benefits business of Evernorth Health Services, has added neffy to its Com...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-adds-neffy-to-commercial-national-formularies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-adds-neffy-to-commercial-national-formularies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2491513333","title":"ARS Pharmaceuticals' Licensing Partners in China, Japan, Australia Seek Approval on Neffy Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2491513333","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491513333?lang=en_us&edition=fundamental","pubTime":"2024-12-13 04:36","pubTimestamp":1734035779,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals (SPRY) said its licensing partners in China, Japan and Australia have submitted approval applications for its epinephrine nasal spray called neffy 2 mg.The phase 3 trial of the nas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","XAO.AU","SPRY","XJO.AU","BK4139"],"gpt_icon":0},{"id":"2491635667","title":"BRIEF-ARS Pharmaceuticals Announces Filings For Approval Of Neffy In China, Japan And Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2491635667","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491635667?lang=en_us&edition=fundamental","pubTime":"2024-12-13 03:54","pubTimestamp":1734033258,"startTime":"0","endTime":"0","summary":"BRIEF-ARS Pharmaceuticals Announces Filings For Approval Of Neffy In China, Japan And AustraliaDec 12 (Reuters) - ARS Pharmaceuticals Inc SPRY.O:ARS PHARMACEUTICALS ANNOUNCES FILINGS FOR APPROVAL OF N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nFWN3ND1MO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2491635614","title":"ARS Pharmaceuticals notes filings for neffy approval in China, Japan, Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2491635614","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491635614?lang=en_us&edition=fundamental","pubTime":"2024-12-13 03:45","pubTimestamp":1734032718,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals (SPRY) announced that its licensing partners in China, Japan and Australia have filed for approval of neffy epinephrine nasal s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-notes-filings-for-neffy-approval-in-china-japan-australia?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-notes-filings-for-neffy-approval-in-china-japan-australia?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRY","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":111,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SPRY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-20","symbol":"SPRY","fiscalQuarterEnding":"2024/12","expectedEps":-0.04,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"pre","actualEps":0.52},{"market":"US","date":"2025-01-13","symbol":"SPRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1736744400000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-11-13","symbol":"SPRY","fiscalQuarterEnding":"2024/09","expectedEps":-0.18,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"pre","actualEps":-0.2},{"market":"US","date":"2024-08-06","symbol":"SPRY","fiscalQuarterEnding":"2024/06","expectedEps":-0.12,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722916800000,"reportTimeType":"post","actualEps":-0.13},{"market":"US","date":"2024-05-09","symbol":"SPRY","fiscalQuarterEnding":"2024/03","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"post","actualEps":-0.11}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SPRY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SPRY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":6,"updateTime":1741320000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SPRY\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SPRY","date":"2025-04-23","current":184.020638,"percent":1,"low":-41.829007,"twenty":-28.563473,"median":-17.701176,"eighty":-11.836649,"high":184.020638,"avg":-12.79323,"sd":37.321686,"marketCap":1471797060},"quantilePoints":[{"date":"2022-11-11","current":-28.534516,"twenty":-28.349227,"median":-28.071294,"eighty":-27.904534,"marketCap":577624216},{"date":"2022-11-18","current":-27.515427,"twenty":-28.349227,"median":-28.00181,"eighty":-27.867476,"marketCap":556994780},{"date":"2022-11-25","current":-28.627161,"twenty":-29.164499,"median":-28.302905,"eighty":-27.978649,"marketCap":579499619},{"date":"2022-12-02","current":-32.332942,"twenty":-29.813011,"median":-28.534516,"eighty":-27.978649,"marketCap":654515751},{"date":"2022-12-09","current":-33.352032,"twenty":-32.629404,"median":-28.951417,"eighty":-27.987913,"marketCap":675145188},{"date":"2022-12-16","current":-37.428392,"twenty":-33.870842,"median":-29.970507,"eighty":-28.034236,"marketCap":757662933},{"date":"2022-12-23","current":-37.428392,"twenty":-36.761351,"median":-31.221208,"eighty":-28.136145,"marketCap":757662933},{"date":"2022-12-30","current":-39.512894,"twenty":-37.428392,"median":-32.842487,"eighty":-28.39555,"marketCap":799859507},{"date":"2023-01-06","current":-33.490999,"twenty":-37.558094,"median":-33.236227,"eighty":-28.506723,"marketCap":677958292},{"date":"2023-01-13","current":-34.510089,"twenty":-37.428392,"median":-33.352032,"eighty":-28.608632,"marketCap":698587729},{"date":"2023-01-20","current":-24.704541,"twenty":-37.261632,"median":-32.981454,"eighty":-28.089644,"marketCap":627322403},{"date":"2023-01-27","current":-23.338221,"twenty":-36.955904,"median":-32.518231,"eighty":-27.978649,"marketCap":592627442},{"date":"2023-02-03","current":-26.292426,"twenty":-36.631648,"median":-30.109473,"eighty":-26.233342,"marketCap":667643574},{"date":"2023-02-10","current":-28.323442,"twenty":-36.44636,"median":-29.576768,"eighty":-26.233342,"marketCap":719217165},{"date":"2023-02-17","current":-31.868488,"twenty":-36.103575,"median":-29.970507,"eighty":-27.026227,"marketCap":809236523},{"date":"2023-02-24","current":-30.539096,"twenty":-35.51065,"median":-30.109473,"eighty":-27.543213,"marketCap":775479264},{"date":"2023-03-03","current":-33.641011,"twenty":-34.760229,"median":-30.612951,"eighty":-27.668279,"marketCap":854246203},{"date":"2023-03-10","current":-29.025066,"twenty":-34.306271,"median":-30.649879,"eighty":-27.867476,"marketCap":737033496},{"date":"2023-03-17","current":-31.056082,"twenty":-33.963486,"median":-30.631415,"eighty":-27.978649,"marketCap":788607087},{"date":"2023-03-24","current":-20.659679,"twenty":-33.801144,"median":-30.612951,"eighty":-27.867476,"marketCap":716518982},{"date":"2023-03-31","current":-17.719962,"twenty":-33.618064,"median":-30.576023,"eighty":-26.2038,"marketCap":614563712},{"date":"2023-04-06","current":-15.732931,"twenty":-33.565575,"median":-30.176574,"eighty":-25.70897,"marketCap":545649501},{"date":"2023-04-14","current":-16.631178,"twenty":-33.492841,"median":-29.970507,"eighty":-24.113699,"marketCap":576802501},{"date":"2023-04-21","current":-17.973502,"twenty":-33.463206,"median":-29.344076,"eighty":-23.419462,"marketCap":623356984},{"date":"2023-04-28","current":-17.210989,"twenty":-33.352032,"median":-29.090384,"eighty":-19.070054,"marketCap":596911536},{"date":"2023-05-05","current":-16.693286,"twenty":-33.350744,"median":-28.918758,"eighty":-18.073817,"marketCap":578956528},{"date":"2023-05-12","current":-12.329028,"twenty":-33.323434,"median":-28.627161,"eighty":-17.841072,"marketCap":427595344},{"date":"2023-05-19","current":-17.294264,"twenty":-33.212652,"median":-28.359496,"eighty":-17.789501,"marketCap":733155735},{"date":"2023-05-26","current":-17.057707,"twenty":-33.123305,"median":-28.101877,"eighty":-17.789501,"marketCap":723127390},{"date":"2023-06-02","current":-15.358643,"twenty":-33.120421,"median":-28.024971,"eighty":-17.719962,"marketCap":651098973},{"date":"2023-06-09","current":-15.179795,"twenty":-32.981454,"median":-27.978649,"eighty":-17.665522,"marketCap":643517035},{"date":"2023-06-16","current":-13.525443,"twenty":-32.939388,"median":-27.584891,"eighty":-17.230009,"marketCap":573384103},{"date":"2023-06-23","current":-14.352619,"twenty":-32.898926,"median":-26.292426,"eighty":-16.984823,"marketCap":608450569},{"date":"2023-06-30","current":-14.777385,"twenty":-32.852687,"median":-26.033933,"eighty":-16.443167,"marketCap":626457673},{"date":"2023-07-07","current":-14.374975,"twenty":-32.778571,"median":-25.664657,"eighty":-16.200645,"marketCap":609398311},{"date":"2023-07-14","current":-15.381,"twenty":-32.650157,"median":-24.815323,"eighty":-15.896248,"marketCap":652046716},{"date":"2023-07-20","current":-16.342312,"twenty":-32.522678,"median":-23.947525,"eighty":-15.738555,"marketCap":692799635},{"date":"2023-07-28","current":-14.889165,"twenty":-32.268091,"median":-23.449004,"eighty":-15.666005,"marketCap":631196385},{"date":"2023-08-04","current":-15.649273,"twenty":-31.980646,"median":-22.434463,"eighty":-15.664922,"marketCap":663419624},{"date":"2023-08-11","current":-12.27233,"twenty":-31.772476,"median":-20.321699,"eighty":-15.577733,"marketCap":654642902},{"date":"2023-08-18","current":-12.05734,"twenty":-31.358888,"median":-18.902086,"eighty":-15.443597,"marketCap":643174706},{"date":"2023-08-25","current":-12.361909,"twenty":-31.218563,"median":-18.499284,"eighty":-15.287104,"marketCap":659421318},{"date":"2023-08-30","current":-12.70231,"twenty":-31.152094,"median":-18.359623,"eighty":-15.152968,"marketCap":677579296},{"date":"2023-09-08","current":-13.114373,"twenty":-31.100395,"median":-18.231502,"eighty":-15.005417,"marketCap":699560007},{"date":"2023-09-15","current":-13.04271,"twenty":-31.033926,"median":-18.031385,"eighty":-14.777385,"marketCap":695737274},{"date":"2023-09-20","current":-11.833393,"twenty":-31.022847,"median":-18.002563,"eighty":-14.750557,"marketCap":631228667},{"date":"2023-09-27","current":-6.718429,"twenty":-31.011769,"median":-17.988032,"eighty":-14.670075,"marketCap":358381151},{"date":"2023-10-05","current":-7.166324,"twenty":-30.867751,"median":-17.964938,"eighty":-14.419687,"marketCap":382273228},{"date":"2023-10-13","current":-6.718429,"twenty":-30.668342,"median":-17.875755,"eighty":-14.196126,"marketCap":358381151},{"date":"2023-10-20","current":-6.055544,"twenty":-30.649879,"median":-17.782874,"eighty":-14.047454,"marketCap":323020877},{"date":"2023-10-27","current":-6.306365,"twenty":-30.649879,"median":-17.728408,"eighty":-14.012806,"marketCap":336400440},{"date":"2023-11-03","current":-6.539271,"twenty":-30.635108,"median":-17.710569,"eighty":-13.713234,"marketCap":348824320},{"date":"2023-11-10","current":-5.319172,"twenty":-30.612951,"median":-17.665522,"eighty":-13.225451,"marketCap":327799293},{"date":"2023-11-17","current":-7.025405,"twenty":-30.612951,"median":-17.36121,"eighty":-12.859969,"marketCap":432947606},{"date":"2023-11-24","current":-7.41484,"twenty":-30.59818,"median":-17.220775,"eighty":-12.627063,"marketCap":456946919},{"date":"2023-12-01","current":-7.523882,"twenty":-30.480012,"median":-17.057707,"eighty":-12.494486,"marketCap":463666727},{"date":"2023-12-08","current":-8.1314,"twenty":-30.216835,"median":-16.553813,"eighty":-12.335604,"marketCap":501105655},{"date":"2023-12-15","current":-8.115823,"twenty":-30.090944,"median":-16.431736,"eighty":-12.243664,"marketCap":500145682},{"date":"2023-12-22","current":-7.944471,"twenty":-30.007565,"median":-16.309818,"eighty":-8.996418,"marketCap":489585985},{"date":"2023-12-29","current":-8.770073,"twenty":-29.979771,"median":-16.222884,"eighty":-8.287174,"marketCap":540464528},{"date":"2024-01-05","current":-8.785651,"twenty":-29.917293,"median":-16.174641,"eighty":-8.399331,"marketCap":541424501},{"date":"2024-01-12","current":-9.112776,"twenty":-29.704533,"median":-16.005127,"eighty":-8.58626,"marketCap":561583924},{"date":"2024-01-19","current":-9.471056,"twenty":-29.440705,"median":-15.977907,"eighty":-8.629876,"marketCap":583663292},{"date":"2024-01-26","current":-10.156461,"twenty":-29.180978,"median":-15.857321,"eighty":-8.707763,"marketCap":625902083},{"date":"2024-02-02","current":-9.969533,"twenty":-29.156298,"median":-15.732931,"eighty":-8.773189,"marketCap":614382412},{"date":"2024-02-09","current":-10.109729,"twenty":-29.07732,"median":-15.682807,"eighty":-8.798113,"marketCap":623022165},{"date":"2024-02-16","current":-11.309188,"twenty":-29.025066,"median":-15.649273,"eighty":-8.900923,"marketCap":696940049},{"date":"2024-02-23","current":-11.83882,"twenty":-29.025066,"median":-15.515136,"eighty":-9.112776,"marketCap":729579115},{"date":"2024-03-01","current":-13.038279,"twenty":-28.81245,"median":-15.453657,"eighty":-9.20624,"marketCap":803496999},{"date":"2024-03-08","current":-13.941768,"twenty":-28.8035,"median":-15.381,"eighty":-9.20624,"marketCap":859175405},{"date":"2024-03-15","current":-14.019655,"twenty":-28.627161,"median":-15.258041,"eighty":-9.237395,"marketCap":863975268},{"date":"2024-03-22","current":-15.975609,"twenty":-28.534516,"median":-15.179795,"eighty":-9.252972,"marketCap":868513986},{"date":"2024-03-28","current":-17.679674,"twenty":-28.423343,"median":-15.269219,"eighty":-9.315282,"marketCap":961155477},{"date":"2024-04-05","current":-16.916395,"twenty":-28.337864,"median":-15.369822,"eighty":-9.405631,"marketCap":919659809},{"date":"2024-04-12","current":-16.401625,"twenty":-28.264358,"median":-15.43689,"eighty":-9.46171,"marketCap":891674358},{"date":"2024-04-19","current":-14.981571,"twenty":-28.131419,"median":-15.49278,"eighty":-9.483518,"marketCap":814473115},{"date":"2024-04-26","current":-14.360297,"twenty":-28.077411,"median":-15.403356,"eighty":-9.636176,"marketCap":780697571},{"date":"2024-05-03","current":-16.860498,"twenty":-28.034236,"median":-15.420123,"eighty":-9.72341,"marketCap":916620967},{"date":"2024-05-10","current":-17.157732,"twenty":-27.987913,"median":-15.505955,"eighty":-9.779488,"marketCap":852670667},{"date":"2024-05-17","current":-17.742813,"twenty":-27.978649,"median":-15.537492,"eighty":-9.809086,"marketCap":881746829},{"date":"2024-05-24","current":-17.157885,"twenty":-27.978649,"median":-15.649273,"eighty":-9.876069,"marketCap":852678252},{"date":"2024-05-31","current":-17.372359,"twenty":-27.867476,"median":-15.716341,"eighty":-9.910338,"marketCap":863336730},{"date":"2024-06-07","current":-17.19688,"twenty":-27.668279,"median":-15.746992,"eighty":-9.932147,"marketCap":854616157},{"date":"2024-06-14","current":-17.430851,"twenty":-27.557105,"median":-15.857321,"eighty":-9.95084,"marketCap":866243588},{"date":"2024-06-21","current":-15.071642,"twenty":-27.270827,"median":-15.857321,"eighty":-9.975764,"marketCap":749000328},{"date":"2024-06-28","current":-15.695565,"twenty":-26.781626,"median":-15.857321,"eighty":-9.988225,"marketCap":780006810},{"date":"2024-07-05","current":-17.723315,"twenty":-26.233342,"median":-15.924221,"eighty":-10.038073,"marketCap":880777877},{"date":"2024-07-12","current":-21.66183,"twenty":-26.100403,"median":-16.005127,"eighty":-10.100383,"marketCap":1076506294},{"date":"2024-07-15","current":-22.129772,"twenty":-26.078246,"median":-16.005127,"eighty":-10.103498,"marketCap":1099761155},{"date":"2024-08-02","current":-20.452979,"twenty":-26.05609,"median":-16.005127,"eighty":-10.106614,"marketCap":1016431235},{"date":"2024-08-09","current":-21.380681,"twenty":-25.915765,"median":-16.072487,"eighty":-10.122191,"marketCap":958752513},{"date":"2024-08-16","current":-29.271428,"twenty":-26.174258,"median":-16.163463,"eighty":-10.15023,"marketCap":1312589385},{"date":"2024-08-23","current":-27.693279,"twenty":-27.713295,"median":-16.214626,"eighty":-10.468009,"marketCap":1241822011},{"date":"2024-08-30","current":-28.060793,"twenty":-27.98643,"median":-16.295121,"eighty":-10.844982,"marketCap":1258302084},{"date":"2024-09-06","current":-25.401719,"twenty":-27.994212,"median":-16.393243,"eighty":-10.985179,"marketCap":1139063905},{"date":"2024-09-13","current":-27.304146,"twenty":-27.978649,"median":-16.401625,"eighty":-11.047488,"marketCap":1224372521},{"date":"2024-09-20","current":-32.125068,"twenty":-28.0393,"median":-16.454093,"eighty":-11.125375,"marketCap":1440552309},{"date":"2024-09-27","current":-31.368421,"twenty":-28.102738,"median":-16.474539,"eighty":-11.25311,"marketCap":1406622746},{"date":"2024-10-04","current":-30.265879,"twenty":-28.279129,"median":-16.592455,"eighty":-11.496117,"marketCap":1357182526},{"date":"2024-10-11","current":-30.071312,"twenty":-28.572704,"median":-16.658407,"eighty":-11.620736,"marketCap":1348457781},{"date":"2024-10-18","current":-34.870616,"twenty":-28.814446,"median":-16.809891,"eighty":-11.676815,"marketCap":1563668153},{"date":"2024-10-25","current":-33.292466,"twenty":-29.051193,"median":-16.869409,"eighty":-11.785716,"marketCap":1492900778},{"date":"2024-10-31","current":-30.849578,"twenty":-29.236068,"median":-16.900657,"eighty":-11.835564,"marketCap":1383356760},{"date":"2024-11-08","current":-34.892234,"twenty":-29.613,"median":-17.040899,"eighty":-11.890396,"marketCap":1564637569},{"date":"2024-11-15","current":-27.926178,"twenty":-29.784002,"median":-17.157809,"eighty":-12.003593,"marketCap":1371287052},{"date":"2024-11-22","current":-26.481379,"twenty":-29.677856,"median":-17.19688,"eighty":-12.129003,"marketCap":1300341655},{"date":"2024-11-29","current":-28.717849,"twenty":-29.625971,"median":-17.210989,"eighty":-12.243664,"marketCap":1410161242},{"date":"2024-12-06","current":-27.708469,"twenty":-29.56544,"median":-17.223194,"eighty":-12.275913,"marketCap":1360596650},{"date":"2024-12-13","current":-25.016789,"twenty":-29.525705,"median":-17.313866,"eighty":-12.298002,"marketCap":1228424404},{"date":"2024-12-20","current":-22.404276,"twenty":-29.458385,"median":-17.352861,"eighty":-12.329028,"marketCap":1100139577},{"date":"2024-12-27","current":-22.067816,"twenty":-29.271428,"median":-17.394358,"eighty":-12.329028,"marketCap":1083618046},{"date":"2025-01-03","current":-21.196979,"twenty":-29.200708,"median":-17.429503,"eighty":-12.355333,"marketCap":1040856437},{"date":"2025-01-10","current":-22.621986,"twenty":-29.176877,"median":-17.469847,"eighty":-12.383408,"marketCap":1110829979},{"date":"2025-01-17","current":-24.106368,"twenty":-29.123341,"median":-17.508842,"eighty":-12.41924,"marketCap":1183719085},{"date":"2025-01-24","current":-27.490759,"twenty":-29.064257,"median":-17.592246,"eighty":-12.455071,"marketCap":1349906247},{"date":"2025-01-31","current":-28.28243,"twenty":-29.064257,"median":-17.626125,"eighty":-12.501652,"marketCap":1388780437},{"date":"2025-02-07","current":-25.333457,"twenty":-29.025066,"median":-17.679674,"eighty":-12.537484,"marketCap":1243974080},{"date":"2025-02-14","current":-23.591782,"twenty":-29.002547,"median":-17.701176,"eighty":-12.573316,"marketCap":1158450862},{"date":"2025-02-21","current":-23.314697,"twenty":-28.938503,"median":-17.719962,"eighty":-12.598398,"marketCap":1144844895},{"date":"2025-02-28","current":-20.187599,"twenty":-28.816442,"median":-17.723315,"eighty":-12.627063,"marketCap":991291845},{"date":"2025-03-07","current":-21.355313,"twenty":-28.81066,"median":-17.742813,"eighty":-12.687977,"marketCap":1048631275},{"date":"2025-03-14","current":-23.651157,"twenty":-28.793317,"median":-17.742813,"eighty":-12.709476,"marketCap":1161366426},{"date":"2025-03-21","current":175.555688,"twenty":-28.745638,"median":-17.756493,"eighty":-12.709476,"marketCap":1404094395},{"date":"2025-03-28","current":154.945377,"twenty":-28.717849,"median":-17.742813,"eighty":-12.566149,"marketCap":1239253124},{"date":"2025-04-04","current":164.39177,"twenty":-28.699711,"median":-17.73561,"eighty":-12.404907,"marketCap":1314805373},{"date":"2025-04-11","current":162.428883,"twenty":-28.621548,"median":-17.723315,"eighty":-12.298002,"marketCap":1299106204},{"date":"2025-04-17","current":182.548472,"twenty":-28.599098,"median":-17.719962,"eighty":-12.05734,"marketCap":1460022683},{"date":"2025-04-23","current":184.020638,"twenty":-28.563473,"median":-17.701176,"eighty":-11.836649,"marketCap":1471797060}],"updateTime":1745490621473}}}